Dietary and pharmacological treatment of abdominal pain in IBS
- PMID: 28232472
- DOI: 10.1136/gutjnl-2016-313425
Dietary and pharmacological treatment of abdominal pain in IBS
Abstract
This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), μ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity.The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1Classes of pharmacological agents for visceral painAntidepressants (tricyclic agents, selective serotonin reuptake inhibitors)Peppermint oil5-HT3 receptor antagonists (alosetron, ondansetron, ramosetron)Non-absorbed antibiotic (rifaximin)Secretagogues (lubiprostone, linaclotide)μ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline)Histamine H1 receptor antagonist (ebastine)Neurokinin-2 receptor antagonist (ibodutant)GABAergic agents (gabapentin and pregabalin).
Keywords: IRRITABLE BOWEL SYNDROME; VISCERAL SENSITIVITY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Comment in
-
Dual histamine blockade for the treatment of adult functional dyspepsia: a single centre experience.Gut. 2020 May;69(5):966. doi: 10.1136/gutjnl-2019-318412. Epub 2019 Apr 30. Gut. 2020. PMID: 31040169 No abstract available.
Similar articles
-
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8. Expert Opin Pharmacother. 2016. PMID: 26559529 Review.
-
Modern Management of Irritable Bowel Syndrome: More Than Motility.Dig Dis. 2016;34(5):566-73. doi: 10.1159/000445265. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27331917 Review.
-
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Pharmacotherapy. 2016. PMID: 26971716 Review.
-
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.Adv Ther. 2020 Jan;37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9. Adv Ther. 2020. PMID: 31707713 Review.
-
Treatment of abdominal pain in irritable bowel syndrome.J Gastroenterol. 2014 Aug;49(8):1193-205. doi: 10.1007/s00535-014-0966-7. Epub 2014 May 21. J Gastroenterol. 2014. PMID: 24845149 Review.
Cited by
-
Circadian dysregulation induces alterations of visceral sensitivity and the gut microbiota in Light/Dark phase shift mice.Front Microbiol. 2022 Sep 13;13:935919. doi: 10.3389/fmicb.2022.935919. eCollection 2022. Front Microbiol. 2022. PMID: 36177467 Free PMC article.
-
Consumption of a Fermented Milk Product Containing Bifidobacterium lactis CNCM I-2494 in Women Complaining of Minor Digestive Symptoms: Rapid Response Which Is Independent of Dietary Fibre Intake or Physical Activity.Nutrients. 2019 Jan 4;11(1):92. doi: 10.3390/nu11010092. Nutrients. 2019. PMID: 30621211 Free PMC article.
-
Randomized clinical trial: the effects of pregabalin for centrally mediated abdominal pain syndrome.Therap Adv Gastroenterol. 2023 Mar 3;16:17562848231152334. doi: 10.1177/17562848231152334. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 36895281 Free PMC article.
-
Effects of Commercial Probiotics on Colonic Sensitivity after Acute Mucosal Irritation.Int J Environ Res Public Health. 2022 May 26;19(11):6485. doi: 10.3390/ijerph19116485. Int J Environ Res Public Health. 2022. PMID: 35682075 Free PMC article.
-
New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.World J Gastroenterol. 2017 Sep 28;23(36):6593-6627. doi: 10.3748/wjg.v23.i36.6593. World J Gastroenterol. 2017. PMID: 29085207 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials